Avalo Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
07/11/2024 14:34
* Avalo Therapeutics Inc AVTX.OQ reported a quarterly
adjusted
loss of $1.25 per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of $-26.40. The mean expectation of two analysts
for the quarter was for a loss of $1.19 per share. Wall Street
expected results to range from $-1.45 to -93 cents per share.
* Revenue rose 5.5% to $249.00 thousand from a year ago;
analysts
expected zero.
* Avalo Therapeutics Inc's reported EPS for the quarter was
98
cents.
* The company reported quarterly net income of $23.04
million.
* Avalo Therapeutics Inc shares had risen by 41.1% this
quarter and gained 47.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 86.5%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Avalo
Therapeutics Inc is 35.00
This summary was machine generated from LSEG data November 7 at
02:34 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -1.19 -1.25 Missed
Jun. 30 2024 -6.70 -14.07 Missed
Mar. 31 2024 -1.18 -1.41 hundred Missed
Dec. 31 2023 -4.80 -1.16 hundred Missed